Przegląd Dermatologiczny (Feb 2025)

Basal Cell Carcinoma: Diagnostic and Therapeutic Management – Expert Opinion of the Polish Dermatological Society

  • Aleksandra Lesiak,
  • Jacek Szepietowski,
  • Joanna Czuwara,
  • Grażyna Kamińska-Winciorek,
  • Joanna Narbutt,
  • Adam Reich,
  • Dorota Kiprian,
  • Joanna Maj,
  • Witold Owczarek,
  • Agnieszka Owczarczyk-Saczonek,
  • Lidia Rudnicka,
  • Irena Walecka,
  • Aleksandra Dańczak-Pazdrowska,
  • Maciej Pastuszczak,
  • Agnieszka Żebrowska,
  • Piotr Rutkowski,
  • Michał Sobjanek,
  • Martyna Sławińska,
  • Małgorzata Sokołowska-Wojdyło,
  • Barbara Zegarska,
  • Wojciech Zegarski,
  • Magdalena Ciażyńska

DOI
https://doi.org/10.5114/dr.2024.149029
Journal volume & issue
Vol. 111, no. 5
pp. 319 – 333

Abstract

Read online

The incidence of skin cancer continues to rise, presenting a significant epidemiological challenge for contemporary medicine. The most prevalent cancer in the Caucasian population is basal cell carcinoma. The gold standard for diagnosing skin cancers remains histopathological examination. However, for low-risk basal cell carcinoma subtypes, non-invasive imaging techniques may suffice to confirm the diagnosis, particularly prior to planned topical or destructive therapies. The guidelines below outline the clinical and pathomorphological subtypes of basal cell carcinoma, its dermoscopic characteristics, staging, and the available options for treatment and prevention of recurrence. The primary and preferred treatment method is the surgical removal of the lesion. The remaining non-surgical methods have lower cure rates and should therefore be reserved for cases with a low risk of recurrence, when surgery is contraindicated or not feasible.

Keywords